NEW YORK (GenomeWeb News) – Epigenomics today announced preliminary revenue growth of 60 percent for full-year 2013.

Revenues for 2013 increased to €1.6 million ($2.2 million) from €1.0 million in 2012 on a strategic collaboration with BioChain in China and increased R&D service fees, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.